BTIM Corp. maintained its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. BTIM Corp.’s holdings in Regeneron Pharmaceuticals were worth $491,000 at the end of the most recent reporting period.
A number of other large investors also recently bought and sold shares of the company. BlackRock Inc. increased its stake in shares of Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock worth $2,381,971,000 after buying an additional 5,967,733 shares during the last quarter. Janus Capital Management LLC boosted its position in Regeneron Pharmaceuticals by 58.5% in the first quarter. Janus Capital Management LLC now owns 1,317,162 shares of the biopharmaceutical company’s stock worth $510,406,000 after buying an additional 486,119 shares during the period. Wellington Management Group LLP boosted its position in Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock worth $2,377,590,000 after buying an additional 446,850 shares during the period. Clearbridge Investments LLC boosted its position in Regeneron Pharmaceuticals by 55.2% in the first quarter. Clearbridge Investments LLC now owns 690,254 shares of the biopharmaceutical company’s stock worth $267,480,000 after buying an additional 245,531 shares during the period. Finally, Harding Loevner LP boosted its position in Regeneron Pharmaceuticals by 76.8% in the first quarter. Harding Loevner LP now owns 557,400 shares of the biopharmaceutical company’s stock worth $215,998,000 after buying an additional 242,162 shares during the period. 66.70% of the stock is owned by institutional investors and hedge funds.
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) opened at 466.59 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $325.35 and a 52-week high of $543.55. The company’s 50-day moving average is $495.54 and its 200-day moving average is $426.50. The stock has a market cap of $49.47 billion, a PE ratio of 46.81 and a beta of 1.66.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. During the same period last year, the business posted $2.82 earnings per share. The firm’s revenue for the quarter was up 21.2% on a year-over-year basis. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post $14.84 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.com-unik.info/2017/08/12/btim-corp-maintains-stake-in-regeneron-pharmaceuticals-inc-nasdaqregn-updated-updated.html.
REGN has been the topic of several research analyst reports. Zacks Investment Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $416.00 price target on the stock in a research note on Thursday, April 27th. Vetr cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $408.86 price target on the stock. in a research note on Monday, April 24th. Credit Suisse Group reiterated a “buy” rating and issued a $485.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, May 5th. UBS AG set a $489.00 price target on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, May 5th. Finally, Canaccord Genuity upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the stock from $375.00 to $484.00 in a report on Friday, May 5th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $489.35.
In other Regeneron Pharmaceuticals news, Chairman P Roy Vagelos sold 9,295 shares of the firm’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $458.14, for a total value of $4,258,411.30. Following the sale, the chairman now directly owns 414,156 shares in the company, valued at $189,741,429.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Sanofi acquired 136,050 shares of the business’s stock in a transaction that occurred on Friday, June 2nd. The shares were bought at an average price of $478.17 per share, for a total transaction of $65,055,028.50. The disclosure for this purchase can be found here. Insiders have sold 56,922 shares of company stock worth $27,383,105 over the last 90 days. 10.40% of the stock is currently owned by company insiders.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
What are top analysts saying about Regeneron Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regeneron Pharmaceuticals Inc. and related companies.